Omega 3 Fatty Acid Efficiency for Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting

• Status: Terminated
• Trial end date: 2013-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate efficacy of Polyunsaturated Fatty Acid for the prevention of Atrial Fibrillation and anti-inflammatory effects in patients after CABG surgery

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Meshalkin Research Institute of Pathology of Circulation
• Treatments: Soybean oil, phospholipid emulsion

Criteria

Inclusion Criteria:

• Elective CABG surgery.

• Signed, documented informed consent prior to admission to the study.

Exclusion Criteria:

• Unstable angina, requiring intervention or CABG <24 hrs after screening.

• Decompensated congestive heart failure.

• Chronic, persistent, paroxysmal atrial fibrillation.

• Uncorrected significant valvular heart disease

• Known hypersensitivity to the study drug

• Left ventricular dysfunction (ejection fraction <35%)

• Use of anti-arrhythmic drugs other than beta blockers

• Non-cardiac illness with a life expectancy of less than 1 year

• Bleeding diathesis or history of coagulopathy

• Significant renal and liver insufficiency

• Significant thyroid, pulmonary disease

• Uncontrolled diabetes mellitus

• Patients on anti-arrhythmic drugs

• Patients with pacemaker

• Patients unable to provide/sign informed consent.

• Patients currently taking marine based omega-three fish oil supplements.

• Disturbances in lipid metabolism, serum triglyceride value >3 mmol/l